Search

Displaying results 4201 - 4210 of 4235 in total
  1. Drug

    R343

    go.drugbank.com/drugs/DB06316
    Investigational

    R343, was investigated in clinical trial NCT01591044 to evaluate its safety and efficacy in patients with mild to moderate asthma.

  2. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  3. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932).

  4. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in metastatic colorectal cancer patie...

  5. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  6. Drug

    BF-1

    go.drugbank.com/drugs/DB06029
    Experimental

    BF-1 is an investigational 5-HT2B receptor antagonist developed for the prophylaxis of Migraines.

  7. Drug

    CX-717

    go.drugbank.com/drugs/DB05047
    IllicitInvestigational

    CX-717 is an ampakine compound previously investigated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and Alzheimer's disease.

  8. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    This organism can invade tissues and produce fatal infections in individuals with compromised immune systems such as those suffering from HIV/AIDS or undergoing organ or bone transplants.

  9. Drug

    Danegaptide

    go.drugbank.com/drugs/DB11821
    Investigational

    Danegaptide has been investigated for the treatment of Focus of Study is STEMI.

  10. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2). OSI-930 is designed to target both cancer cell proliferation and blood vessel growth (angio...